LYEL
Lyell Immunopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$460.35M
P/E Ratio
—
EPS
$-16.06
Beta
-0.07
52W High
$45.00
52W Low
$7.65
50-Day MA
$22.31
200-Day MA
$19.86
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Fundamentals
| Revenue (TTM) | 36,000 |
| Gross Profit (TTM) | 36,000 |
| EBITDA | $-186.75M |
| Operating Margin | -1024633.00% |
| Return on Equity | -87.00% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.68 |
| Price-to-Book | 1.85 |
| Price-to-Sales (TTM) | 12787.52 |
| EV/Revenue | 7336.8 |
| EV/EBITDA | 0.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -45.50% |
| Shares Outstanding | $23.33M |
| Float | $10.37M |
| % Insiders | 35.44% |
| % Institutions | 53.63% |
Historical Volatility
HV 10-Day
59.04%
HV 20-Day
72.03%
HV 30-Day
67.47%
HV 60-Day
76.38%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($34.80 target)
1
Strong Buy2
Buy1
Strong SellData last updated: 5/1/2026